A Cost-Benefit Comparison of Intensive Diabetes Management With Implantable Pumps Versus Multiple Subcutaneous Injections in Patients With Type I Diabetes
The DOI matches its Crossref record.
Abstract
OBJECTIVE: To investigate if intraperitoneal (IP) insulin infusion via programmable implantable pumps is a potential alternative to subcutaneous (SC) insulin via multiple injections. RESEARCH DESIGN AND METHODS: We compared the cost-benefits of the two methods using a randomized, prospective, 6-month, crossover design in 10 adult type I diabetic patients. RESULTS: When judged on the last month of IP versus SC periods in the nine patients who completed the study, metabolic data showed better glycemie control (HbA1c: 7.2 ± 0.2 IP vs. 8.5 ± 0.7% SC, mean ± SE, P = 0.02), reduced glycemie fluctuations (SD of capillary glucose values: 3.4 ± 0.2 IP vs. 4.6 ± 0.2 mM SC, P > 0.01), and fewer mild hypoglycemie events (5.7±2.0 IP vs. 10.0 ± 3.1 events/month SC, P = 0.02). Quality of life, judged by Diabetes Control and Complications Trial questionnaires, was unaffected by pump therapy. Direct costs, including pump acquisition, implantation, and follow-up, were 2.6-fold higher with IP than with SC delivery. CONCLUSIONS: The implantable pump is more effective in the short term, equally accepted, but more costly than multiple injections and should be limited to patients with unsatisfactory glycemie control despite intensive diabetes management with SC insulin. In addition, longer-term, larger-scale, and comparative evaluation is required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Peripheral Peril: Injected Insulin Induces Insulin Insensitivity in Type 1 Diabetes
Gregory, J. M., Cherrington, A. D., & Moore, D. J. (2020) · Diabetes · doi:10.2337/dbi19-0026 · Cited by 76
Implantable insulin pumps. A position statement about their clinical use
Renard, E., & Schaepelynck-Bélicar, P. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2006.10.004 · Cited by 69
Glycemic Parameters with Multiple Daily Injections Using Insulin Glargine Versus Insulin Pump
Garg, S. K., Walker, A. J., Hoff, H. K., D'Souza, A. O., Gottlieb, P. A., & Chase, H. P. (2004) · Diabetes Technology & Therapeutics · doi:10.1089/152091504322783350 · Cited by 60
“10,11 The CSII therapy is more expensive 12 than MDI therapy and has the disadvantage of pump malfunctions and secondary diabetic ketoacidosis (DKA).”
Spaan, N., Teplova, A., Stam, G., Spaan, J., & Lucas, C. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0557-3 · Cited by 46
Modeling Intraperitoneal Insulin Absorption in Patients with Type 1 Diabetes
Schiavon, M., Cobelli, C., & Dalla Man, C. (2021) · Metabolites · doi:10.3390/metabo11090600 · Cited by 6
Metadata
- Authors
- Haardt, M.-J., Selam, J.-L., Slama, G., Bethoux, J.-P., Dorange, C., Mace, B., Ramaniche, M.-L., & Bruzzo, F.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1994-08-01
- Volume
- 17
- Issue
- 8
- Pages
- 847-851
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2098487077
- Cited by
- 49
- References
- 0
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Cost-Benefit Comparison of Intensive Diabetes Management With Implantable Pumps Versus Multiple Subcutaneous Injections in Patients With Type I Diabetes. https://app.cochat.ai/papers/10.2337/diacare.17.8.847
- The paper
- Haardt, M.-J., Selam, J.-L., Slama, G., Bethoux, J.-P., Dorange, C., Mace, B., Ramaniche, M.-L., & Bruzzo, F. (1994). A Cost-Benefit Comparison of Intensive Diabetes Management With Implantable Pumps Versus Multiple Subcutaneous Injections in Patients With Type I Diabetes. Diabetes Care. https://doi.org/10.2337/diacare.17.8.847
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.